Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4457-4462

  Harms, Wibke ^a   Malter, Wolfram ^a   Krämer, Stefan ^a   Drebber, Uta ^a   Drzezga, Alexander ^a   Schmidt, Matthias ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Breast cancer; Plasminogen activator inhibitor type 1 (PAI 1); Sentinel lymph node biopsy; Urokinase type plasminogen activator (uPA)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIMARY TUMOR; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE METASTASIS; BREAST TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 (PAI-1); SENTINEL LYMPH NODE BIOPSY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA);

BREAST CANCER; PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 (PAI-1); SENTINEL LYMPH NODE BIOPSY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA);

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84908689754     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Robert Koch-Institut: Cancer in Germany 2009/2010. Federal Health Reports of Germany, Robert Koch-Institut, Berlin, 9th Edition, pp. 68-71, 2013.
2. Arbeitsgemeinschaft Gynäkologische Onkologie e.V.: Diagnosis and therapy of primary and metastasized breast carcinomas. Guidelines Breast Version 2013.1D (http://www.ago-online.de), 2013.
3. Straver ME, Meijnen P, van Tienhoven G et al: Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 17: 1854-1861, 2010.
4. Vogt H, Schmidt M, Bares R et al: Procedure guideline for sentinel lymph node diagnosis. Nuklearmedizin 2010 49: 167-172, 2010.
5. Harbeck N, Kates RE, Gauger K et al: Urokinasetype plasminogen activator uPA and its inhibitor PAI-1: novel tumour-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 91: 450-456, 2004.
6. Andreasen PA, Kjoller L, Christensen L et al: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
7. Schmitt M, Wilhelm O, Reuning U et al: The plasminogen activation system as a novel target for therapeutic strategies. Fibrinolysis 14: 114-132, 2000.
8. Duffy MJ, O'Grady P, Devaney D et al: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62: 531-533,1988.
9. Jänicke F, Schmitt M, Ulm K et al: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 2: 1049, 1989.
10. Jänicke F, Schmitt M and Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17: 303-312, 1991.
11. Kim SJ, Shiba E, Kobayashi T et al: Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 19: 177-182, 1998.
12. Foekens JA, Peters HA and Look MP et al: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636-643, 2000.
13. Cufer T, Borstnar S and Vrhovec I: Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 18: 106-115, 2003.
14. Harbeck N, Schmitt M, Vetter M et al: Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. Breast Care 3(suppl 2): 11-15, 2008.
15. Harbeck N, Kates RE and Schmitt M: Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualised therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20: 1000-1009, 2002.
16. Konecny G, Untch M, Arboleda J et al: Her2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 7: 2448-2457, 2001.
17. Bouchet C, Ferrero-Pous M, Hacene K et al: Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma. Int J Biol Markers 18: 207-217, 2003.
18. Zemzoum I, Kates RE, Ross JS et al: Invasion factors uPA/ PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 21: 1022-1028, 2003.
19. Look MP, van Putten WLK, Duffy MJ et al: Pooled analysis of prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002.
20. Zemzoum I, Kates RE, Ross JS et al: Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 21(6): 1022-1028, 2003.
21. Harbeck N, Alt U, Berger U et al: Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy. Clin Cancer Res 7: 2757-2764, 2001.
22. Danø K, Andreasen PA, Grøhndahl-Hansen J et al: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
23. Schmitt M, Jänicke F and Graeff H: Tumor-associated proteases. Fibrinolysis 6: 3-26, 1992.
24. Cubellis MV, Wun TC and Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085, 1990.
25. Harbeck N, Thomssen C, Berger U et al: Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Research and Treatment 54: 147-157, 1999.
26. Harbeck N, Schmitt M, Meisner C et al: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. European Journal of Cancer 49: 1825-1835, 2003.
27. Sweep CGJ, Geurts-Moe spot J and Grebenschikov N et al: External quality assessment oftrans-European multicenter antigen determinations (enzyme-linked immuno sorbent assay) of urokinase-type plasminogen activator (uPA)and its type-1 inhibitor (PAI-1)in human breast cancer tissue extracts. Br J Cancer 78: 1434-1441, 1998.
28. Thomssen C, Harbeck N, Dittmer J et al: Feasibility of measuring the prognostic factors uPA and PAI-1 incore needle biopsy breast cancer specimens. J Natl Cancer Inst 101(14): 1028-1029, 2009.
29. Hayes DF, Bast R, Desch CE et al: A tumour marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumour markers. J Natl Cancer Inst 88: 1456-1466, 1996.
30. Knoop A, Andreasen PA, Andersen JA et al: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77: 932-940, 1998.
31. Cufer T, Vrhovec I and Borstnar S: Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival. Int J Biol Markers 17: 33-41, 2002.
32. Harbeck N, Thomssen C, Berger U et al: Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 54: 147-157, 1999.
33. Harbeck N, Schmitt M, Kates RE et al: Clinical Utility of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1 Determination in Primary Breast Cancer Tissue for Individualized Therapy Concepts Clinical Breast Cancer 3(3): 196-200, 2002.
34. Jänicke F, Prechtl A, Thomssen C et al: Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I. J Natl Cancer Inst 93: 913-920, 2001.
35. Ferroni P, Roselli M, Portarena I et al: Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. Anticancer Res 34(3): 1153-1161, 2014.
36. Vénat-Bouvet L, Fermeaux V, Leobon S et al: Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases. Anticancer Res 34(3): 1213-1217, 2014.